The US Food and Drug Administration (FDA) believes that the
contamination of Baxter's blood thinner heparin, which has been
linked to 62 deaths in the US, may have been due to the deliberate
replacement of some ingredients with...
At present India appears to be beating China in the race for Asia's
top clinical spot, according to new figures published by india´s
Planning Commission.
Despite all the hype over clinical trial offshoring, the US still
dwarfs the scene, with emerging countries as yet only a blip on the
radar, a unique new study reveals.
The pharmacopoeias of the US and China will work more closely
together in future in a bid to improve the quality of medicines
available in both countries.
The continuing clinical trials globalisation trend will cause the
complexity of running these studies to dramatically increase by
2010, according to a new report.
Pharmaceutical manufacturers, distributors and retailers alike have
welcomed a unanimous vote by the California State Board of Pharmacy
to delay for another two years the implementation of electronic
pedigree requirements for tracking...
The globalisation of the supply chain increasingly challenges the
US Food and Drug Administration's ability to ensure the quality of
pharmaceuticals on the US market, acknowledges the acting director
of the agency's Center...
Novartis has lent impetus to the growing trend towards
philanthropic R&D in the pharmaceutical industry by opening a
new research institute in Siena, Italy "with a non-profit
mission to exclusively focus on the development...
Chinese outsourcing firm Radiant Pharma & Tech is blasting
through the stereotypes being pinned on companies operating in
low-cost economies, with the relatively young firm hoping to give
companies in established markets a run...
Members of the Synthetic Organic Chemical Manufacturers Association
(SOCMA) have slammed competitors from emerging markets, claiming
poor quality goods and lack of technological competence in regions
such as China, India and Eastern...
Outsourcing will be seen as being "instrumental" in the
eyes of healthcare and biopharma firms this year as the focus on
cost reduction continues to increase, according to a new report.
Product recalls in the UK due to health and safety concerns have
shot up to their highest level, with the rise in outsourcing to
China finger pointed for much of the blame.
As of next year Chinese pharmaceutical manufacturers will face a
tougher time gaining good manufacturing practice (GMP)
certification after the country's regulator signalled new and
stricter standards were on the way.
This week two sets of contract research organisations (CROs) have
announced plans to link arms in order to spread their reach further
into this increasingly globalised marketplace.
